Evidence map›Paper›PMID 32577635›Full record

ArticlebioRxiv : the preprint server for biology2020

Human iPSC-derived alveolar and airway epithelial cells can be cultured at air-liquid interface and express SARS-CoV-2 host factors.

Kristine M Abo, Liang Ma, Taylor Matte, Jessie Huang, Konstantinos D Alysandratos, Rhiannon B Werder, Aditya Mithal, Mary Lou Beermann, Jonathan Lindstrom-Vautrin, Gustavo Mostoslavsky and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  3. Human-Based AdvancedFrontiers in medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kristine M AboCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Liang MaCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Taylor MatteCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Jessie HuangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Konstantinos D AlysandratosCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Rhiannon B WerderCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Aditya MithalCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Mary Lou BeermannCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Jonathan Lindstrom-VautrinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Gustavo MostoslavskyCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Laertis IkonomouCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Finn HawkinsCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Andrew WilsonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Carlos Villacorta-MartinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.

Funding

Editing Alveolar Progenitor Cells for Correction of Monogenic DiseaseU01HL134745 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTON, DARRELL N., MORRISEY, EDWARD E · 2016 to 2022
$8.3M
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damageU01HL134766 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A, KOTTON, DARRELL N. · 2016 to 2022
$8.1M
Derivation of Transplantable Lung Epithelial Progenitors from iPS CellsR01HL095993 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton · 2009 to 2026
$7.5M
A National iPS Cell Network with Deep Phenotyping for Translational ResearchU01TR001810 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILAD, YOAV, KOTTON, DARRELL N. · 2016 to 2020
$4.4M
Training Program in Cardiovascular Biology: Pre-DoctoralT32HL007969 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2003 to 2019
$3.2M
A National Resource for Lung disease-specific iPS cellsR24HL123828 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N., MOSTOSLAVSKY, GUSTAVO · 2014 to 2018
$2.7M
Thyroid Hormone Signaling in Human HepatocytesR01DK117940 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI HOLLENBERG, ANTHONY N, WILSON, ANDREW A · 2019 to 2022
$2.7M
NATIONAL BIOREPOSITORY OF LUNG DISEASE-SPECIFIC HUMAN INDUCED PLURIPOTENT STEM CELLS:THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL75N92020C00005 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI N/A, N/A · 2021 to 2024
$2.6M
Personalized therapy for AATD-associated liver disease via IPS modelingR01DK101501 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WILSON, ANDREW A · 2015 to 2019
$2.4M
iPSC-Derived Airway Basal Cells to Model Human Airway Development and DiseaseR01HL139799 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAWKINS, FINN · 2018 to 2022
$2.1M
Generation of functional lung stem cells from human iPSCsU01HL148692 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Finn Hawkins, Darrell N. Kotton · 2019 to 2026
$2.0M
Pluripotent stem cell-based modeling of cigarette smoke injuryF30HL147426 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ABO, KRISTINE · 2020 to 2023
$160k
NCATS NIH HHS U01 TR001810NHLBI NIH HHS 75N92020C00005NHLBI NIH HHS F30 HL147426NHLBI NIH HHS R01 HL095993NHLBI NIH HHS R01 HL139799NHLBI NIH HHS R24 HL123828NHLBI NIH HHS T32 HL007969NHLBI NIH HHS U01 HL134745NHLBI NIH HHS U01 HL134766NHLBI NIH HHS U01 HL148692NIDDK NIH HHS R01 DK101501NIDDK NIH HHS R01 DK117940
6 · The paper itself

Abstract

Development of an anti-SARS-CoV-2 therapeutic is hindered by the lack of physiologically relevant model systems that can recapitulate host-viral interactions in human cell types, specifically the epithelium of the lung. Here, we compare induced pluripotent stem cell (iPSC)-derived alveolar and airway epithelial cells to primary lung epithelial cell controls, focusing on expression levels of genes relevant for COVID-19 disease modeling. iPSC-derived alveolar epithelial type II-like cells (iAT2s) and iPSC-derived airway epithelial lineages express key transcripts associated with lung identity in the majority of cells produced in culture. They express

Identifiers

PMID32577635
PMCPMC7302183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.